ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,975Medicare Part D Prescriptions Filled, Including Refills

Rank: 26 out of 262

$397K Total Retail Price of All Prescriptions

Rank: 50 out of 262

513 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Dakota
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 513 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

8% of this provider’s 513 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

2% of this provider’s 8,644 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$40 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Dakota
LEVOTHYROXINE SODIUM 452 400 1 2
SIMVASTATIN 444 386 2 1
FUROSEMIDE 391 354 3 4
LISINOPRIL 297 283 4 3
POTASSIUM CHLORIDE 283 236 5 10
OMEPRAZOLE 277 241 6 5
METFORMIN HCL 266 215 7 9
ATENOLOL 265 249 8 16
HYDROCHLOROTHIAZIDE 251 234 9 7
AMLODIPINE BESYLATE 243 205 10 6
SERTRALINE HCL 208 185 11 14
GABAPENTIN 206 158 12 19
WARFARIN SODIUM 170 161 13 12
ATORVASTATIN CALCIUM 160 147 14 13
METOPROLOL TARTRATE 160 160 14 8
HYDROCODONE-ACETAMINOPHEN 127 85 S3 16 15
ADVAIR DISKUS 127 104 16 34
TAMSULOSIN HCL 112 78 18 25
ALENDRONATE SODIUM 110 101 19 21
TRAMADOL HCL 109 85 20 18
CITALOPRAM HBR 105 102 21 20
ENALAPRIL MALEATE 103 91 22 27
ALLOPURINOL 91 77 23 22
GLIPIZIDE 86 70 24 70
DONEPEZIL HCL 84 84 25 23
DOXAZOSIN MESYLATE 83 78 26 59
FENTANYL 80 80 S2 27 40
AMITRIPTYLINE HCL 79 49 R 28 68
GLYBURIDE 79 75 R 28 89
LOSARTAN POTASSIUM 79 74 28 17
FINASTERIDE 73 61 31 73
MIRTAZAPINE 71 71 32 35
CARBIDOPA-LEVODOPA 68 68 33 66
QUINAPRIL HCL 67 67 34 107
PREDNISONE 66 65 35 29
PRAVASTATIN SODIUM 66 61 35 41
LOSARTAN-HYDROCHLOROTHIAZIDE 64 61 37 43
AVODART 59 59 38 120
RANITIDINE HCL 58 57 39 62
AZITHROMYCIN 57 47 40 44
OXYBUTYNIN CHLORIDE 57 55 40 90
RISPERIDONE 56 56 42 50
ZETIA 56 37 42 60
JANTOVEN 55 55 44 39
CRESTOR 55 52 44 30
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 10, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.